Literature DB >> 9836374

Joint inflammation and cartilage destruction may occur uncoupled.

W B van den Berg1.   

Abstract

Chronic arthritis is characterized by a persistent joint inflammation and concomitant joint destruction. Although the joint swelling is a major clinical problem, destruction of bone and cartilage may occur uncoupled to inflammation and it is of utmost importance to fully understand the elements of the destructive process. TNF and IL-1 are considered master cytokines in the process of human RA, with a claimed cascade of TNF inducing most of the IL-1 production. Studies in experimental models revealed that TNF is indeed a pivotal cytokine in joint swelling, yet IL-1 is the dominant cartilage destructive cytokine and its production may occur independent of TNF. This was found with anti-TNF/IL-1 neutralizing antibodies and the observations were recently backed up with similar data in arthritis models in TNF and IL-1 knockout mice. Apart from the absolute level of IL-1, the destructive potential of an arthritis is determined by the balance with regulatory cytokines and anabolic growth factors. IL-4, IL-6, and IL-10 can promote inflammation and tissue fibrosis, yet cartilage destruction is found to be greatly reduced by these cytokines, linked to a range of pathways which can reduce the IL-1 impact on the articular cartilage. Finally, the presence of anabolic growth factors in the inflamed synovium may have a major impact on net destruction. Endogenous transforming growth factor-beta (TGF-beta) is found in inflamed synovia, but local coadministration of TGF-beta further enhanced the degree of synovitis, yet almost fully prevented cartilage damage, providing another example of a major lack of correlation between inflammatory mass and destructive potential. It is suggested that novel therapy in RA patients should not only focus on reduction of outer signs of joint inflammation, but should also include attempts at reduction of cartilage destruction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836374     DOI: 10.1007/bf00832004

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  52 in total

1.  Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigen-induced arthritis.

Authors:  J B van Meurs; P L van Lent; I I Singer; E K Bayne; F A van de Loo; W B van den Berg
Journal:  Arthritis Rheum       Date:  1998-04

2.  Dynamic expression of transforming growth factor-betas (TGF-beta) and their type I and type II receptors in the synovial tissue of arthritic rats.

Authors:  A Müssener; K Funa; S Kleinau; L Klareskog
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

3.  Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA.

Authors:  S S Makarov; J C Olsen; W N Johnston; S K Anderle; R R Brown; A S Baldwin; J S Haskill; J H Schwab
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

4.  Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation.

Authors:  A A van de Loo; W B van den Berg
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

5.  Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.

Authors:  P L Van Lent; F A Van De Loo; A E Holthuysen; L A Van Den Bersselaar; H Vermeer; W B Van Den Berg
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

6.  Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone.

Authors:  E Lubberts; L A Joosten; M M Helsen; W B van den Berg
Journal:  Cytokine       Date:  1998-05       Impact factor: 3.861

7.  The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice.

Authors:  L Probert; D Plows; G Kontogeorgos; G Kollias
Journal:  Eur J Immunol       Date:  1995-06       Impact factor: 5.532

8.  Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice.

Authors:  S Georgopoulos; D Plows; G Kollias
Journal:  J Inflamm       Date:  1996

9.  Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.

Authors:  P H Wooley; J Dutcher; M B Widmer; S Gillis
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

10.  Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy.

Authors:  K Otani; I Nita; W Macaulay; H I Georgescu; P D Robbins; C H Evans
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

View more
  20 in total

1.  Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells.

Authors:  Jingsong Wang; John W Fathman; Geanncarlo Lugo-Villarino; Lucila Scimone; Ulrich von Andrian; David M Dorfman; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2006-01-12       Impact factor: 14.808

2.  Punica granatum L. extract inhibits IL-1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappaB in human chondrocytes in vitro.

Authors:  Salahuddin Ahmed; Naizhen Wang; Bilal Bin Hafeez; Vinay K Cheruvu; Tariq M Haqqi
Journal:  J Nutr       Date:  2005-09       Impact factor: 4.798

Review 3.  Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis.

Authors:  M H Schiff
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 4.  Arguments for interleukin 1 as a target in chronic arthritis.

Authors:  W B van den Berg
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  Decline after immobilisation and recovery after remobilisation of synovial fluid IL1, TIMP, and chondroitin sulphate levels in young beagle dogs.

Authors:  J Haapala; J P Arokoski; S Rönkkö; U Agren; V M Kosma; L S Lohmander; M Tammi; H J Helminen; I Kiviranta
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

6.  Lifelong voluntary joint loading increases osteoarthritis in mice housing a deletion mutation in type II procollagen gene, and slightly also in non-transgenic mice.

Authors:  T Lapveteläinen; M M Hyttinen; A-M Säämänen; T Långsjö; J Sahlman; S Felszeghy; E Vuorio; H J Helminen
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

7.  Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease.

Authors:  Phyllissa Schmiedlin-Ren; Laura J Reingold; Christopher S Broxson; Ahren C Rittershaus; Josh S Brudi; Jeremy Adler; Scott R Owens; Ellen M Zimmermann
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-25       Impact factor: 4.052

8.  Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation.

Authors:  Shahla Abdollahi-Roodsaz; Leo A B Joosten; Marije I Koenders; Ben T van den Brand; Fons A J van de Loo; Wim B van den Berg
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

9.  Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.

Authors:  N A Graudal; M Svenson; U Tarp; P Garred; A-G Jurik; K Bendtzen
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

10.  Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.

Authors:  T J M Smeets; E C Barg; M C Kraan; M D Smith; F C Breedveld; P P Tak
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.